Nocturnal IOP lower with elevated head

Article

When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a newly published study.

When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a study newly published in the Journal of Glaucoma..

Thirty patients - 15 who said they had glaucoma and 15 who said they did not - participated in the prospective, non-randomized comparative case series. Each of them slept in a sleep laboratory on 2 different nights, 1 night lying in a supine position and the other lying on a wedge-shaped pillow at a 20-degree head-up position. The researchers measured baseline IOP at 10 pm while participants were awake and then measured IOP every 2 hours while participants slept, at midnight, 2 am, 4 am and 6 am.

Position did not significantly affect IOP as measured when participants were awake. When participants were sleeping, however, mean IOP was 1.51 mmHg higher when participants were in the supine position than when they were in the head-up position, with an average increase of 1.56 mmHg in those with glaucoma and 1.47 mmHg in those without the disease. In fact, 25 of the 30 patients had lower mean IOP when they were in the 20-degree head-up position than when lying flat. For 11 of them, mean IOP reduction was more than 10%.

To read an abstract of the study or download the full article, go to the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.